Prior Authorization Recommended

Prior authorization is recommended for cranial electrotherapy stimulation (CES) and auricular electrostimulation requests to ensure appropriate indication, prior conservative care, and evidence documentation are available for review.

• Require prior-authorization submission for CES and auricular electrostimulation devices and programs.
• Verify member benefits and applicable contract language prior to authorization review.

Prior Authorization: Evidence Expectations

When prior authorization is requested, submit higher-quality comparative evidence where available. Preference is for randomized controlled trials and well-conducted comparative prospective studies; single-arm and observational data may be considered only for safety or longer-term outcomes when comparative data are unavailable.

• Expect submission of RCTs or comparative trials when claiming clinical benefit.
• If relying on nonrandomized evidence, provide justification and detailed methodology to address bias concerns.

Prior Authorization: Device and Outcome Documentation

If authorization is required for a specific device, include device-specific rationale and outcome measurement plans. Documentation should link the requested device to the indication and specify validated clinical endpoints that will be used to assess benefit.

• Provide device name, model, FDA status/clearance, and rationale for device selection.
• List planned outcome measures (e.g., HAM-D, Beck inventories, SAI, Wexner Constipation Score, COWS) and the timeline for assessment.

Evidence Does Not Support Use for Several Indications

The current evidence does not support CES for depression, anxiety, Parkinson disease, smoking cessation, tic disorders, or other listed psychiatric/neurologic indications due to mixed RCT results, methodological limitations, and lack of consistent superiority over sham.

• Requests for CES for these indications should include high-quality comparative evidence showing clinically meaningful benefit over standard care or sham.
• Absent such evidence, services may be considered investigational and not covered.

Avoid Duplicative or Overlapping Studies

Studies with duplicative or overlapping populations were excluded from evidence synthesis; when submitting evidence, avoid relying on overlapping cohorts and clearly identify unique populations and follow-up periods.

• Provide study dates, sites, and enrollment criteria to establish that populations are not duplicated across submissions.
• If overlapping data are submitted, indicate how the dataset is unique or justify inclusion.

Benefit Verification and Applicable Contract

Verify member benefits and the applicable contract prior to authorization or billing. Coverage may vary by contract, and exclusions or limitations could apply.

• Confirm benefit existence, any exclusions, and prior-authorization requirements before scheduling or providing services.
• Document benefit verification in the prior-authorization submission.

Evidence Review Methods and Selection

Evidence reviews prioritize randomized controlled trials and other comparative prospective trials for efficacy assessment. Methodologic selection favors minimizing bias and ensuring relevance to the intended clinical use.

• Highlight comparative trial design, blinding, sham credibility, and adherence data in submissions.
• Explain relevance to the intended population and comparator intensity (e.g., medical management, biofeedback).

Required Clinical Documentation for Authorization

Required clinical documentation for prior-authorization review should include validated baseline and follow-up measures, prior conservative therapy history, and device-specific treatment plans.

• Provide baseline and follow-up scores using validated instruments relevant to the indication (e.g., HAM-D, Beck Depression Inventory, State Anxiety Inventory, Wexner Constipation Score, COWS).
• Document trials of prior conservative therapies (medication, psychotherapy, biofeedback, behavior modification, dietary changes, laxatives) and duration of each trial.
• Include device settings, duration/frequency of treatment, adherence monitoring plan, and anticipated clinical milestones.

Documentation Required for Functional Constipation Indication

For CES in functional constipation, authorization should include documentation that patients meet Rome III criteria and have undergone or been recommended for biofeedback; provide objective and patient-reported outcome measures.

• Confirm Rome III criteria are met and include the Wexner Constipation Score at baseline and follow-up.
• Document prior recommendation for biofeedback and whether biofeedback was attempted; if combined with CES, describe the comparative rationale.

Selection Prioritized for Comparative Controlled Trials

Selection of evidence for authorization decisions prioritizes comparative controlled trials, preferably randomized and sham-controlled, to establish superiority over standard comparators.

• Provide comparative data versus medical management, biofeedback, behavior modification, or other conservative therapies as appropriate.
• If step therapy applies, document trials and failures of standard pharmacotherapy or psychotherapy prior to requesting CES or auricular electrostimulation.

Recommended Documentation for Opioid Withdrawal Cases

For auricular electrostimulation used in opioid withdrawal, provide baseline and follow-up Clinical Opioid Withdrawal Scale (COWS) scores and detailed treatment protocol information to support authorization.

• Submit baseline COWS and serial COWS measurements (e.g., 20, 30, 60 minutes, and day 5) when relevant.
• Describe device implantation/use protocol, monitoring during initial treatment, clinician training, and follow-up schedule.

Billing and Coding Guidance

Use appropriate CPT, HCPCS, Revenue, and ICD diagnosis codes when submitting claims; incorrect or unsupported coding may lead to claim denial.

• Relevant codes cited in source: CPT 0783T (transcutaneous auricular neurostimulation set-up/education).
• HCPCS examples: A4543, A4596, E1399, E0721, E0732; S8930 (auricular acupuncture point electrical stimulation, per 15 minutes).
• Include correct diagnosis codes that justify medical necessity and align with the documented indication.

Comparators Considered

Comparators considered in evidence assessment include medical management and other conservative therapies (medication, biofeedback, behavior modification, physical exercise, stress management, dietary modification, and laxatives where applicable).

• Document prior trials of these comparators and their durations when seeking authorization.
• When CES or auricular electrostimulation is proposed as adjunctive therapy, provide rationale and comparative evidence.

Step Therapy Consideration

Step therapy considerations: prior trials and failure of standard therapy (e.g., pharmacotherapy, psychotherapy, biofeedback) may be required before coverage of CES or auricular electrostimulation is approved.

• Document medication trials, behavioral therapy attempts, or biofeedback with dates, doses, durations, and outcomes.
• If step therapy was bypassed, provide clinical rationale for why standard therapies are not appropriate or have been contraindicated.